9 Oak Park Drive
285 articles with Insulet Corporation
Omnipod System to be Highlighted at the 54th Annual Meeting of the European Association for the Study of Diabetes in Berlin, Germany
Insulet Corporation today announced plans to release its financial results for the third quarter of 2018 on November 1, 2018
Insulet Announces Shacey Petrovic, President and COO, Promoted to CEO, Effective January 1, 2019; Patrick Sullivan Will Retire as Chairman and CEO at the End of 2018
Timothy Scannell Will Become Chairman of the Board
Insulet Corporation today announced that management will present at two upcoming investor conferences in New York City, New York:
Insulet to Showcase Its Omnipod DASH™ Insulin Management System at the American Association of Diabetes Educators Annual Conference
Insulet Corporation announced it will showcase its recently FDA cleared Omnipod DASH™ Insulin Management System (Omnipod DASH System), during the American Association of Diabetes Educators meeting at the Baltimore Convention Center in Baltimore, Maryland on August 17-20, 2018.
Insulet Reports Second Quarter 2018 Revenue of $124.3 Million, Up 13% Year-Over-Year, and Gross Margin of 66%, Up 710 Basis Points
Full Year 2018 Expected Revenue Growth Revised to 18% to 21%
Insulet Corporation announced that it has partnered with Glooko®, Inc. to connect Insulet’s Omnipod System user data with Glooko+diasend®
Insulet Corporation announced plans to release its financial results for the second quarter of 2018 on August 2, 2018 after the close of the financial markets.
Insulet Partners with the International Diabetes Federation Europe to Support Advocacy Activities Across the Continent
Insulet Corporation announced it has entered into a partnership with the European Region of the International Diabetes Federation (IDF Europe) to collaborate on regional advocacy activities.
Tubeless, Waterproof* Insulin Pump and Wireless, Handheld Personal Diabetes Manager Make Switching from Multiple Daily Injections to Pump Therapy Much Easier
Insulet has established a dedicated Customer Care team, committed to providing best-in-class support to its large European customer base.
Insulet to Unveil New Omnipod® DASHTM System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions
Insulet Corporation announced it will showcase its recently FDA cleared Omnipod DASHTM Insulin Management System (Omnipod DASH System), during the American Diabetes Association (ADA) 78th Scientific Sessions
Insulet Corporation announced FDA 510(k) clearance of the Omnipod DASHTM Insulin Management System (Omnipod DASH).
May 29, 2018 20:01 UTC BILLERICA, Mass.--( BUSINESS WIRE )-- Insulet Corporation (NASDAQ: PODD) (Insulet), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at the William Blair & Company 38 th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 12, 2018 at 12:50 p.m. (Central Time). To listen to a live au
Insulet Reports First Quarter 2018 Revenue of $123.6 Million, Up 21% Year-Over-Year, and Gross Margin of 61.4%, Up 300 Basis Points, Exceeding Expectations
Insulet Corporation announced financial results for the three months ended March 31, 2018.
Insulet Achieves Key Milestones to Support its Transition to Direct Operations in Europe on July 1, 2018
Insulet Corporation announced that it has achieved key milestones as it transitions to direct operations in Europe on July 1st.
The difference between the salaries paid to top executives and the median income earned by rank and file employees has been a sore subject for many years and has served as a wedge political issue in recent elections.
Sarepta Therapeutics is breathing a little easier this morning. On Wednesday a federal appeals court supported a previous court’s decision to dismiss charges that the company misled shareholders as it vied to gain approval for its Duchenne muscular dystrophy treatment.
Insulet Corporation announced plans to release its financial results for the first quarter of 2018 on May 3, 2018 after the close of the financial markets.
Insulet Corporation announced that it will have a strong presence at three leading national diabetes congresses in Europe over the coming months.